AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
ELEVANCE HEALTH INC (ELV) Scores Highest on Martin Zweig's Growth Investor Model with a 69% Rating.
ByAinvest
Friday, Nov 28, 2025 4:08 pm ET1min read
Elevance Health Inc (ELV) scores 69% using Martin Zweig's Growth Investor model, which looks for stocks with accelerating earnings and sales growth, reasonable valuations, and low debt. ELV passes tests on P/E ratio, revenue growth in relation to EPS growth, current quarter earnings, quarterly earnings one year ago, EPS growth for current quarter, and earnings persistence. However, it fails tests on sales growth rate, earnings growth rate for the past several quarters, long-term EPS growth, and insider transactions.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet